What do bivalent vaccines mean for Australia’s rollout? The first doses of Moderna’s variant-specific COVID vaccine became available this week, offering a slight advantage over previous versions.
In Practice: Recognition for antiviral rollout GPs have been thanked by Australia’s Chief Medical Officer for spearheading the rollout of COVID-19 antiviral treatments.
‘A constellation of symptoms’: Long COVID in focus The first public hearing into long COVID has taken place as clinicians attempt to work out the scale of the problem, and one GP reports a rising demand for treatment.
Doubts over impact of key antiviral treatment A large UK study suggests molnupiravir has no effect on hospitalisations and deaths but reduces the overall recovery time from COVID-19.
Confusion as Government walks back bivalent dose commitment Australia will not receive 15 million doses of variant-specific vaccines from Moderna in 2022.
TGA approves second COVID-19 vaccine for youngest children The Pfizer vaccine is now approved for use in children aged six months to five years, with Moderna already available to the age group.
In Practice: Feedback requested for long COVID inquiry Members can participate in a survey to help inform the college’s submission to the recently announced long COVID inquiry.
Independent review into COVID vaccine procurement released Eight recommendations have been handed down, with the next two years identified as ‘critical’ to Australia’s recovery.
TGA approves vaccine booster for primary school age children Pfizer’s COVID-19 vaccine has been given the green light as a booster for children aged 5–11, with ATAGI recommendations to follow.
All excess deaths in Singapore linked to recent COVID infection: Study A new report from the country’s Ministry of Health attributes the increased death rate to COVID-19’s aggravation of existing illnesses.